Table 1.
Ongoing Therapeutic Clinical Trials in Adult sALCL in the Relapsed/Refractory Setting
| Diseases Studied | Brief Description | Study Design |
Study Drugs | Primary Endpoint |
Recruitment Status |
Location | NCT Number |
|---|---|---|---|---|---|---|---|
| CD30+ HL, ALCL | Combination of BV and Bendamustine in Relapsed or Refractory HL or ALCL | Phase 1/2; Open-label | BV + Bendamustine | Safety/Efficacy | Recruiting | Multicenter, Canada | NCT01657331 |
| ALK+ ALCL | BV and Imatinib in Patients With RR ALK+ ALCL or Patients Ineligible for Chemotherapy | Open-label; pilot study | BV + Imatinib | Safety/Efficacy | Not open yet | Austria | NCT02462538 |
| CD30 ALCL | A Phase 2 Study of BV in Treatment of Patients With RR sALCL | A Phase 2; Open-label | BV | Best clinical response (ORR) | Active, not recruiting | International | NCT00866047 |
| sALCL | Study of BV in Patients With RR sALCL | Phase 4; Open-label | BV | ORR | Recruiting | Europe | NCT01909934 |
| CD30+ Lymphoma | A Pilot Study of Weekly BV in Patients With CD30+ Malignancies Refractory to Every 3 Week BV | Pilot; Open-label | BV weekly | ORR | Recruiting | United States | NCT01703949 |
| CD30+ HL, ALCL | BV Maintenance After AlloSCT in High Risk CD30+ Lymphoma | Phase 2; Open-label | BV | - Graft Failure Incidence - Safety |
Recruiting | United States | NCT02169505 |
| CD30+ HL, ALCL | BV (Recombinant) for IV Infusion - Special Drug Use Surveillance in RR CD30+ HL or ALCL | Observational; Prospective cohort | BV (recombinant) | Frequency of adverse events | Recruiting | Japan | NCT02139592 |
| ALK+ ALCL; Solid tumors with ALK or MEK pathway alterations | Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET “CREATE” | Phase 2; Open-label | Crizotinib | Anti-tumor activity | Recruiting | Multicenter, Europe (EORTC) | NCT01524926 |
| NSCLC or any other tumor with ALK rearrangement | A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | Phase 1/2; Open-label | ALK/EGFR Inhibitor AP26113 | Phase 2 dose finding; ORR | Active, Not Recruiting | United States, Spain | NCT01449461 |
| PTCL | Alisertib in Treating Patients With RR PTCL | Phase 2; Open-label | Alisertib | Aurora Kinase expression; ORR | Active, Not Recruiting | United States, Canada | NCT01466881 |
| HL; B-Cell NHL; PTCL | Alisertib in Combination With Vorinostat in Treating Patients With RR HL, B-Cell NHL, or PTCL | Phase 1 | Alisertib + Vorinostat | MTD; Toxicities | Active, Not Recruiting | United States | NCT01567709 |
| T-cell NHL; HL | CPI-613 and Bendamustine in Treating Patients With RR T-Cell NHL or HL | Phase 1 | CPI-613 + Bendamustine | MTD | Recruiting | United States | NCT02168140 |
| T-Cell Lymphoma | Carfilzomib in Treating Patients With RR T-Cell Lymphoma | Phase 1 | Carfilzomib | MTD | Active, Not Recruiting | United States | NCT01336920 |
| Lymphoid Malignancies | Panobinostat in Treating Patients With RR NHL | Phase 2; Open-label | Panobinostat | ORR | Recruiting | United States | NCT01261247 |
| Lymphoid Malignancies | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | Phase 2; Open-label | Akt Inhibitor MK2206 | ORR | Recruiting | United States | NCT01258998 |
| Lymphoid Malignancies | Monoclonal Antibody Therapy Before SCT in Patients With RR Lymphoid Malignancies | Phase 1 | yttrium-90 anti-CD45 mAb BC8 | MTD | Recruiting | United States | NCT01678443 |
| CD30+ Lymphomas | Safety and Efficacy of 4th Generation CAR T-Cells Targeting RR CD30+ Lymphomas | Phase 1/2; Open-label | CAR T-cells | Safety/Efficacy | Recruiting | United States, China | NCT02274584 |
Abbreviations. ALCL: anaplastic large cell lymphoma; AlloSCT: allogeneic stem cell transplant; BV: brentuximab vedotin; FL: follicular lymphoma; HL: Hodgkin lymphoma; MCL mantle cell lymphoma; MTD: maximum tolerated dose; NHL: non-Hodgkin lymphoma; NSCLC: non-small cell lung carcinoma; ORR: objective response rate; PFS: progression-free survival; PTCL: peripheral T-cell lymphoma; RR: relapsed/refractory. Data from ClinicalTrials.gov (accessed September 8, 2015).